MS Trial Alert: Investigators Recruiting for Study Comparing Exercise Programs to Improve Depression
Feb 08, 2012
Summary: Investigators at the University of Washington, Seattle, are recruiting 108 people with all types of MS or spinal cord injury nationwide for a study comparing the effects on depression of two telephone-coordinated exercise programs. The study, also called the inMotion study, is funded by the National Institutes on Disability and Rehabilitation Research.
MS Trial Alert: Pain Study Recruiting People with MS Nationwide
Feb 07, 2012
Summary: Investigators nationwide are recruiting 400 people with secondary-progressive MS or relapsing-remitting MS to compare the effectiveness of three doses of the oral drug AVP-923 (Nuedexta®, dextromethorphan hydrobromide and quinidine sulfate, Avanir Pharmaceuticals) or inactive placebo in reducing central neuropathic pain. The study is funded by Avanir Pharmaceuticals.
MS Trial Alert: Investigators Recruiting for Studies Comparing Ocrelizumab to Rebif® in People with Relapsing MS
Jan 17, 2012
Summary: Investigators worldwide are recruiting a total of 1600 people with relapsing MS (http://www.nationalmssociety.org/about-multiple-sclerosis/relapsing-ms/index.aspx) for two phase III studies comparing the effectiveness of intravenous ocrelizumab (Genentech) versus Rebif® (interferon beta-1a, EMD Serono & Pfizer). Ocrelizumab, an experimental therapy, is also being tested in primary-progressive MS (http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=5797). The study is funded by F. Hoffmann-La Roche Ltd.
MS Trial Alert: Investigators Recruiting for Study of Ocrelizumab in Primary-Progressive MS
Dec 19, 2011
Summary: Investigators worldwide are recruiting 630 people with primary-progressive MS (http://www.nationalmssociety.org/about-multiple-sclerosis/progressive-ms/primary-progressive-ms/index.aspx) to study the effectiveness of intravenous ocrelizumab (Genentech) versus inactive placebo. This experimental therapy is also being tested in relapsing MS. The study is funded by F. Hoffmann-La Roche Ltd.
MS Trial Alert: Recruiting for a Nationwide Study of an Investigational New Treatment for Spasticity
Oct 17, 2011
Summary: Investigators nationwide are recruiting 200 people with any type of MS for a study comparing several doses of an investigational study drug, arbaclofen placarbil (AP), which is similar to a currently approved medication, baclofen, with inactive placebo. The study is funded by XenoPort, Inc.
MS Trial Alert: Investigators Recruiting for Study Comparing Telephone-Delivered Self-Management Programs to Improve MS Symptoms
Sep 21, 2011
Summary: Investigators at the University of Washington, Seattle, are recruiting up to 200 people with all types of MS nationwide for a study comparing the effects of two telephone-delivered self-management programs targeting pain, fatigue, and depression. The study, also called Take Charge, is funded by the National Institutes on Disability and Rehabilitation Research (NIDRR) as part of the Rehabilitation Research and Training Center for Multiple Sclerosis (MSRRTC) at the University of Washington.
Update: Ohio Stem Cell Study Recruiting People with MS -- Study supported by the CDMRP, thanks in large part to MS activists who helped secure funding
Aug 23, 2011
Summary: Investigators in Ohio are recruiting 24 people for first study in U.S. of the safety of transplanting one’s own mesenchymal stem cells (derived from bone marrow) in relapsing forms of MS.
MS Trial Alert: Investigators Recruiting for Study of Tysabri in Secondary-Progressive MS
Aug 23, 2011
Summary: Investigators worldwide are recruiting over 800 people with secondary-progressive MS (http://www.nationalmssociety.org/about-multiple-sclerosis/relapsing-ms/secondary-progressive-ms-spms/index.aspx) to determine the effectiveness of natalizumab (Tysabri®, Biogen Idec and Elan) at reducing the progression of disability in this population. The study, also known as the ASCEND study, is sponsored by Biogen Idec.
MS Trial Alert: Investigators Studying ELND002, Subcutaneous Drug in 125 People with Relapsing MS
Jul 13, 2011
Summary: Investigators are recruiting 125 people with relapsing MS in the United States and Canada to determine the safety and effectiveness of ELND002, a variation of an alpha-4-integrin inhibitor delivered via injection under the skin. Elan Pharmaceuticals is sponsoring the study.
MS Trial Alert: Drug Study at NIH Recruiting People with Secondary-Progressive MS
Jun 16, 2011
Summary: Researchers at the National Institutes of Health in Bethesda, Maryland are looking to recruit 80 people with secondary-progressive Multiple Sclerosis (secondary-progressive MS) to evaluate the safety and effectiveness of rituximab. Rituximab is an experimental drug for treating MS. In this study it will be given intravenously and directly into the cerebrospinal fluid by lumbar puncture (“spinal tap”). The study is funded by the National Institute of Neurological Disorders and Stroke.
MS Trial Alert: Clinical Trial of Sex Hormone Estriol Recruiting Women with MS to Participate - Updated
Jun 10, 2011
Summary: The National MS Society is funding a team of investigators at 15 medical centers to conduct a two-year, controlled clinical trial of an estrogen (estriol) added to standard therapy to treat MS.
MS Trial Alert: Study of Oral Teriflunomide (HMR1726) Added on to Interferon Beta Recruiting People with Relapsing Forms of MS Worldwide
May 03, 2011
Summary:Investigators in the United States and others around the world are recruiting 1455 people with relapsing multiple sclerosis for a study comparing two doses of oral teriflunomide (HMR1726), an investigational medication, or inactive placebo, in people taking any type of approved interferon beta. The study is sponsored by Sanofi.
MS Trial Alert: Investigators in Oregon Recruiting People with Relapsing MS for Study of Effects of Low-fat Diet on MS Disease Activity; Travel Costs Covered
Apr 08, 2011
Summary: Investigators at Oregon Health & Science University are recruiting 54 people with relapsing-remitting MS (http://www.nationalmssociety.org/about-multiple-sclerosis/relapsing-ms/relapsing-remitting-ms-rrms/index.aspx) for a study comparing the effectiveness of a low-fat diet program versus no intervention in controlling disease activity in MS. Please note: The study requires six clinic visits to Portland, Oregon, and a 10-day visit for diet training to Santa Rosa, California. Travel costs are covered by the study.
MS Trial Alert: Sites in 18 States Recruiting for a Trial of Abatacept for People with Relapsing- Remitting MS
Mar 18, 2011
Summary: Investigators in 18 states are conducting a trial to test the safety and effectiveness of abatacept, an experimental drug administered intravenously, in 123 people with relapsing-remitting MS, versus inactive placebo. The trial also is known as the ACCLAIM trial, and is being conducted by the Immune Tolerance Network and sponsored by the National Institute for Allergy and Infectious Disease.
Early Clinical Trial Results and Observational Study Support Further Research of “Probiotic” Parasitic Worm Treatment Approach in MS
Mar 18, 2011
Two recently published studies are reporting results related to parasitic worms, called helminths, and their possible implications for treating multiple sclerosis. Further study, including the second phase of the reported clinical trial supported by the National MS Society, should determine whether a “probiotic” treatment approach using relatively harmless parasitic worms to alter immune activity will benefit people with MS.
MS Trial Alert: Drug Study at NIH Recruiting People with Primary-Progressive MS
Jan 26, 2011
Summary: Researchers at the National Institutes of Health in Bethesda, Maryland are looking to recruit 80 people with Primary-Progressive Multiple Sclerosis to evaluate the safety and effectiveness of Idebenone, an oral experimental drug. The study is funded by the National Institute of Neurological Disorders and Stroke.
Nerve Repair Teams Convened to Share Exciting Progress and Plan Next Steps
Jan 26, 2011
A cure for MS means not just stopping and ending the disease but repairing damage and restoring lost function. The Nervous System Repair and Protection Initiative, funded through the National MS Society’s Promise: 2010 Campaign, was launched in 2005 to address what was then an underexplored area. This bold initiative involved the largest grants ever offered by the Society and set the stage for translating basic lab discoveries into clinical efforts to restore nerve function in people with MS. The results have been impressive: it jump-started the field, trained scores of promising young investigators, produced over 150 research papers, and leveraged millions of dollars in new funding.
MS Trial Alert: Investigators Recruiting for Trial Studying Safety of Adding BG00012 to MS Treatments
Oct 29, 2010
Summary: Investigators are recruiting 100 people with relapsing-remitting MS nationwide to participate in a study to determine the safety of adding the experimental oral drug BG00012 to interferon beta (Avonex®, Biogen Idec; Betaseron®, Bayer HealthCare Pharmaceuticals; or Rebif®, EMD Serono) or Copaxone® (glatiramer acetate, Teva Pharmaceutical Industries). The phase 2 study is funded by Biogen Idec. Everyone enrolled in the study will receive BG00012 therapy, as there is no placebo group in this open-label study.
MS Trial Alert: Investigators in Alabama Seeking Participants for Physical Therapy Study in MS
Aug 13, 2010
Summary: Investigators at the University of Alabama at Birmingham are recruiting 66 people with relapsing-remitting, secondary-progressive, or primary-progressive MS to participate in a study comparing the effectiveness of two types of physical therapy for increasing movement (improving nonuse) of the arm in MS.
MS Trial Alert: Study Recruiting People to Study JC Virus Levels in People Taking Tysabri
May 21, 2010
Summary: Investigators nationwide are recruiting people with relapsing MS who are taking Tysabri® (natalizumab, Biogen Idec and Elan Pharmaceuticals). The primary goal of this study is to better understand whether the incidence of PML (progressive multifocal leukoencephalopathy, a severe brain infection caused by JC virus) in Tysabri-treated patients who do not have detectable antibodies to JC virus (antibody negative) is lower than in patients who have detectable antibodies to JC virus (antibody positive ).
MS Trial Alert: Investigators in Buffalo Recruiting for Research Study on Venous Insufficiency, or CCSVI, in People with MS and Others
Dec 22, 2009
Summary: Investigators at the University of Buffalo are recruiting 1600 adults and 100 children for a research study investigating the frequency of CCSVI (http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=2206) in people with MS when compared to healthy controls and controls with other neurological disorders.
MS Trial Alert: Investigators Recruiting 1500 People with MS for Study of PEGylated Interferon Beta-1a
Aug 31, 2009
Summary: Investigators worldwide are recruiting 1500 people with relapsing MS for a Phase III clinical trial comparing the effectiveness of BIIB017 (PEGylated interferon beta-1a, delivered under the skin) and inactive placebo. The study is sponsored by Biogen Idec.
MS Trial Alert: Small Study Recruiting People with MS and Spasticity to Compare IPX056 (Extended-release Baclofen) and Immediate-release Baclofen
Jul 14, 2009
Summary: Investigators at seven sites in the United States are recruiting 28 people for a study comparing the effect of the experimental compound IPX056 (extended-release baclofen) to currently available, immediate-release baclofen in relieving spasticity and symptoms related to MS. The study is sponsored by Impax Pharmaceuticals, a division of Impax Laboratories, Inc.
MS Trial Alert: Recruiting Patients for Study on How Adhering to Therapy Impacts MS
Jun 25, 2009
Summary: A new study is seeking to determine to what extent individuals’ sticking to their prescribed treatment regimen (called “compliance”) affects outcomes in relapsing-remitting MS, and whether special programs can enhance their adherence to therapy.
Exploring Why Physical Activity is Reduced in People with MS: Society-funded Investigators Seek Participants
Aug 19, 2008
Investigators funded by the National MS Society are seeking people with MS to participate in a study exploring whether the frequency and severity of MS-related symptoms influence physical activity.
MS Trial Alert: France: Small Study of PI-2301, Co-polymer, Recruiting People with Secondary-Progressive MS
May 19, 2008
Investigators in France are recruiting up to 53 people with secondary-progressive MS for a study comparing PI-2301 (Peptimmune, Inc.) with inactive placebo.
MS Trial Alert: Study of Long-term Safety of Tysabri® To Enroll 2500 in North America
Apr 04, 2008
Investigators are enrolling 2500 people with relapsing forms of MS at sites in the United States and Canada to study the long-term safety of routine use of Tysabri® (natalizumab, Biogen Idec and Elan Pharmaceuticals). Biogen Idec is sponsoring this study.